## Olga Gruzdeva

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6118916/olga-gruzdeva-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53	<b>522</b> citations	12	<b>2</b> O
papers		h-index	g-index
65	686	<b>2.4</b> avg, IF	3.93
ext. papers	ext. citations		L-index

#	Paper	IF	Citations
53	Expression of adipocytokine in heart fat depots depending on the degree of coronary artery atherosclerosis in patients with coronary artery disease. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , <b>2021</b> , 76, 159-168	0.4	1
52	Analysis of probable lipotoxic damage and myocardial fibrosis in epicardial obesity. <i>Aging</i> , <b>2021</b> , 13, 14	1806614	1815
51	Possibilities of neurocognitive rehabilitation using the dual tasks method in patients in the early postoperative period of coronary bypass surgery. <i>Cardiosomatics</i> , <b>2021</b> , 12, 200-205	0.4	1
50	Relationship of visceral obesity and coronary calcinosis in ischemic heart disease. <i>Terapevticheskii Arkhiv</i> , <b>2021</b> , 93, 1428-1434	0.9	
49	Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myocardial Infarction in Patients with Preserved Ejection Fraction. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	4
48	Predictors of myocardial fibrosis and loss of epicardial adipose tissue volume in the long-term period after myocardial infarction. <i>Russian Journal of Cardiology</i> , <b>2020</b> , 25, 31-40	1.3	4
47	In-hospital changes of echocardiographic parameters and their relationship with the procollagen I C-terminal propeptide in patients with myocardial infarction and preserved left ventricle systolic function. <i>Russian Journal of Cardiology</i> , <b>2020</b> , 25, 45-51	1.3	
46	The relationship of the epicardial fat and adipo-fibrokines in myocardial infarction. <i>Klinichescheskaya Laboratornaya Diagnostika</i> , <b>2020</b> , 65, 533-540	0.5	1
45	Ceramides: focus on obesity. Obesity and Metabolism, <b>2020</b> , 17, 307-315	0.6	1
44	Relationship between epicardial and perivascular fatty tissue and adipokine-cytokine level in coronary artery disease patients. <i>PLoS ONE</i> , <b>2019</b> , 14, e0208156	3.7	10
43	Increased Serum Parathyroid Hormone, Osteocalcin and Alkaline Phosphatase Are Associated with a Long-Term Adverse Cardiovascular Outcome after Coronary Artery Bypass Graft Surgery. <i>Diagnostics</i> , <b>2019</b> , 9,	3.8	2
42	Adipocytes Directly Affect Coronary Artery Disease Pathogenesis via Induction of Adipokine and Cytokine Imbalances. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2163	8.4	16
41	Adipokine gene expression in adipocytes isolated from different fat depots of coronary artery disease patients. <i>Archives of Physiology and Biochemistry</i> , <b>2019</b> , 1-9	2.2	3
40	The role of perivascular adipose tissue in the development of cardiovascular diseases. The importance of diagnosis for assessing the risk stratification of cardiovascular diseases. <i>Terapevticheskii Arkhiv</i> , <b>2019</b> , 91, 130-135	0.9	
39	The marker of adverse prognosis 1.5-anhydroglucitol in patients with coronary heart disease in the long-term period after planned myocardial revascularization. <i>Terapevticheskii Arkhiv</i> , <b>2019</b> , 91, 48-52	0.9	
38	The relationship of epicardial obesity and levels of cardiac fibrosis markers. <i>Russian Journal of Cardiology</i> , <b>2019</b> , 13-19	1.3	3
37	Biological markers and cardiac remodelling following the myocardial infarction. <i>Aging</i> , <b>2019</b> , 11, 3523-	35 <b>36</b>	1

## (2017-2019)

36	Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy?. <i>Obesity and Metabolism</i> , <b>2019</b> , 16, 12-19	0.6	
35	Polyvascular disease in patients with myocardial infarction and chronic kidney disease. <i>Terapevticheskii Arkhiv</i> , <b>2019</b> , 91, 73-79	0.9	2
34	Leptin resistance: underlying mechanisms and diagnosis. <i>Diabetes, Metabolic Syndrome and Obesity:</i> Targets and Therapy, <b>2019</b> , 12, 191-198	3.4	104
33	Calcium Phosphate Bions Cause Intimal Hyperplasia in Intact Aortas of Normolipidemic Rats through Endothelial Injury. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	9
32	Relationships between epicardial adipose tissue thickness and adipo-fibrokine indicator profiles post-myocardial infarction. <i>Cardiovascular Diabetology</i> , <b>2018</b> , 17, 40	8.7	28
31	The role of newly diagnosed diabetes mellitus for poor in-hospital prognosis of coronary artery bypass grafting. <i>Diabetes Mellitus</i> , <b>2018</b> , 21, 344-355	1.6	6
30	PRE-SURGERY STATUS AND IN-HOSPITAL COMPLICATIONS OF CORONARY BYPASS GRAFTING IN PREDIABETES AND TYPE 2 DIABETES PATIENTS. <i>Russian Journal of Cardiology</i> , <b>2018</b> , 40-48	1.3	7
29	Epicardial adipose tissue: pathophysiology and role in the development of cardiovascular diseases. <i>Bulletin of Siberian Medicine</i> , <b>2018</b> , 17, 254-263	0.4	3
28	Influence of visceral obesity on the secretion of adipokines with epicardial adipocytes in patients with coronary heart disease. <i>Terapevticheskii Arkhiv</i> , <b>2018</b> , 90, 71-78	0.9	3
27	Leptin resistance: unsolved diagnostic issues. <i>Problemy Endokrinologii</i> , <b>2018</b> , 64, 62-66	Ο	5
27 26	Leptin resistance: unsolved diagnostic issues. <i>Problemy Endokrinologii</i> , <b>2018</b> , 64, 62-66  Advantages and disadvantages of different methods for diagnosis of visceral obesity. <i>Obesity and Metabolism</i> , <b>2018</b> , 15, 3-8	0.6	5
	Advantages and disadvantages of different methods for diagnosis of visceral obesity. <i>Obesity and</i>		
26	Advantages and disadvantages of different methods for diagnosis of visceral obesity. <i>Obesity and Metabolism</i> , <b>2018</b> , 15, 3-8	0.6	5
26 25	Advantages and disadvantages of different methods for diagnosis of visceral obesity. <i>Obesity and Metabolism</i> , <b>2018</b> , 15, 3-8  Localization of fat depots and cardiovascular risk. <i>Lipids in Health and Disease</i> , <b>2018</b> , 17, 218  Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery. <i>Clinical</i>	0.6	5
26 25 24	Advantages and disadvantages of different methods for diagnosis of visceral obesity. <i>Obesity and Metabolism</i> , <b>2018</b> , 15, 3-8  Localization of fat depots and cardiovascular risk. <i>Lipids in Health and Disease</i> , <b>2018</b> , 17, 218  Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery. <i>Clinical Hemorheology and Microcirculation</i> , <b>2017</b> , 66, 57-66  Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with	o.6 4.4 2.5 o.8	5 59 2
26 25 24 23	Advantages and disadvantages of different methods for diagnosis of visceral obesity. <i>Obesity and Metabolism</i> , <b>2018</b> , 15, 3-8  Localization of fat depots and cardiovascular risk. <i>Lipids in Health and Disease</i> , <b>2018</b> , 17, 218  Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery. <i>Clinical Hemorheology and Microcirculation</i> , <b>2017</b> , 66, 57-66  Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease. <i>Bulletin of Experimental Biology and Medicine</i> , <b>2017</b> , 163, 608-611  Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with	o.6 4.4 2.5 o.8	5 59 2 47
26 25 24 23 22	Advantages and disadvantages of different methods for diagnosis of visceral obesity. <i>Obesity and Metabolism</i> , <b>2018</b> , 15, 3-8  Localization of fat depots and cardiovascular risk. <i>Lipids in Health and Disease</i> , <b>2018</b> , 17, 218  Use of thrombin generation test for monitoring hemostasis in coronary bypass surgery. <i>Clinical Hemorheology and Microcirculation</i> , <b>2017</b> , 66, 57-66  Adipokine and Cytokine Profiles of Epicardial and Subcutaneous Adipose Tissue in Patients with Coronary Heart Disease. <i>Bulletin of Experimental Biology and Medicine</i> , <b>2017</b> , 163, 608-611  Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2017</b> , 10, 481-48  Serum neutrophil gelatinase-associated lipocalin the estimation of hospital prognosis in patients	0.6 4.4 2.5 0.8	5 59 2 47

18	Adipokine-cytokine profile of adipocytes of epicardial adipose tissue in ischemic heart disease complicated by visceral obesity. <i>Obesity and Metabolism</i> , <b>2017</b> , 14, 38-45	0.6	2
17	Body fat distribution: the answer to the apparent paradox of obesity in cardiology?. <i>Obesity and Metabolism</i> , <b>2017</b> , 14, 3-8	0.6	5
16	The role of adipose tissue and adipokines in the manifestation of type 2 diabetes in the long-term period following myocardial infarction. <i>Diabetology and Metabolic Syndrome</i> , <b>2016</b> , 8, 24	5.6	13
15	Is visceral obesity the cause of obesity paradox?. <i>Problemy Endokrinologii</i> , <b>2016</b> , 62, 33-39	Ο	5
14	Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction. <i>Annals of Laboratory Medicine</i> , <b>2016</b> , 36, 313-9	3.1	15
13	Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction. <i>Disease Markers</i> , <b>2016</b> , 2016, 1549063	3.2	2
12	Early Effects of Treatment Low-Dose Atorvastatin on Markers of Insulin Resistance and Inflammation in Patients with Myocardial Infarction. <i>Frontiers in Pharmacology</i> , <b>2016</b> , 7, 324	5.6	12
11	Glucose levels as a prognostic marker in patients with ST-segment elevation myocardial infarction: a case-control study. <i>BMC Endocrine Disorders</i> , <b>2016</b> , 16, 31	3.3	16
10	Association of inflammatory markers and poor outcome in diabetic patients presenting with ST segment elevation myocardial infarction. <i>Journal of Inflammation Research</i> , <b>2015</b> , 8, 107-16	4.8	3
9	Dose-dependent effects of atorvastatin on myocardial infarction. <i>Drug Design, Development and Therapy</i> , <b>2015</b> , 9, 3361-8	4.4	8
8	Impact of recipient-related factors on structural dysfunction of xenoaortic bioprosthetic heart valves. <i>Patient Preference and Adherence</i> , <b>2015</b> , 9, 389-99	2.4	8
7	The role of cystatin C in the prognosis of adverse outcomes after the coronary artery bypass graft surgery during hospitalisation. <i>Heart Lung and Circulation</i> , <b>2015</b> , 24, 193-9	1.8	2
6	Lipid, adipokine and ghrelin levels in myocardial infarction patients with insulin resistance. <i>BMC Cardiovascular Disorders</i> , <b>2014</b> , 14, 7	2.3	13
5	Multivessel coronary artery disease, free fatty acids, oxidized LDL and its antibody in myocardial infarction. <i>Lipids in Health and Disease</i> , <b>2014</b> , 13, 111	4.4	19
4	Insulin resistance and inflammation markers in myocardial infarction. <i>Journal of Inflammation Research</i> , <b>2013</b> , 6, 83-90	4.8	16
3	Relationship between free fatty acids, insulin resistance markers, and oxidized lipoproteins in myocardial infarction and acute left ventricular failure. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2013</b> , 6, 103-11	3.4	9
2	Plasminogen activator inhibitor-1, free fatty acids, and insulin resistance in patients with myocardial infarction. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2013</b> , 6, 293-301	3.4	5
1	Leptin resistance: unsolved diagnostic issues. <i>Problemy Endokrinologii</i> ,64, 62-66	О	